Chimeric Antigen Receptor T Cell Therapy Market, Global Outlook and Forecast 2022-2028

June 2022 | 100 pages | ID: C241A2FFC089EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Chimeric Antigen Receptor T Cell Therapy in Global, including the following market information:

Global Chimeric Antigen Receptor T Cell Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chimeric Antigen Receptor T Cell Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Allogeneic Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chimeric Antigen Receptor T Cell Therapy include Amgen, Bellicum Pharmaceuticals, Bluebird Bio, Caribou Biosciences, Celgene Corporation, Cellectis, Celyad Oncology, Gilead Sciences and Intellia Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chimeric Antigen Receptor T Cell Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chimeric Antigen Receptor T Cell Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chimeric Antigen Receptor T Cell Therapy Market Segment Percentages, by Type, 2021 (%)

• Allogeneic
• Autologous

Global Chimeric Antigen Receptor T Cell Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chimeric Antigen Receptor T Cell Therapy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Universities and Colleges
• Others

Global Chimeric Antigen Receptor T Cell Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chimeric Antigen Receptor T Cell Therapy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chimeric Antigen Receptor T Cell Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chimeric Antigen Receptor T Cell Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Amgen
• Bellicum Pharmaceuticals
• Bluebird Bio
• Caribou Biosciences
• Celgene Corporation
• Cellectis
• Celyad Oncology
• Gilead Sciences
• Intellia Therapeutics
• Johnson & Johnson
• Legend Biotech
• Merck
• Noile-Immune Biotech
• Novartis
• Pfizer
• Sangamo Therapeutics
• Servier Laboratories

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Chimeric Antigen Receptor T Cell Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Chimeric Antigen Receptor T Cell Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY OVERALL MARKET SIZE

2.1 Global Chimeric Antigen Receptor T Cell Therapy Market Size: 2021 VS 2028
2.2 Global Chimeric Antigen Receptor T Cell Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Chimeric Antigen Receptor T Cell Therapy Players in Global Market
3.2 Top Global Chimeric Antigen Receptor T Cell Therapy Companies Ranked by Revenue
3.3 Global Chimeric Antigen Receptor T Cell Therapy Revenue by Companies
3.4 Top 3 and Top 5 Chimeric Antigen Receptor T Cell Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chimeric Antigen Receptor T Cell Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chimeric Antigen Receptor T Cell Therapy Players in Global Market
  3.6.1 List of Global Tier 1 Chimeric Antigen Receptor T Cell Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Chimeric Antigen Receptor T Cell Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Chimeric Antigen Receptor T Cell Therapy Market Size Markets, 2021 & 2028
  4.1.2 Allogeneic
  4.1.3 Autologous
4.2 By Type - Global Chimeric Antigen Receptor T Cell Therapy Revenue & Forecasts
  4.2.1 By Type - Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2022
  4.2.2 By Type - Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2023-2028
  4.2.3 By Type - Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Chimeric Antigen Receptor T Cell Therapy Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Universities and Colleges
  5.1.4 Others
5.2 By Application - Global Chimeric Antigen Receptor T Cell Therapy Revenue & Forecasts
  5.2.1 By Application - Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2022
  5.2.2 By Application - Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2023-2028
  5.2.3 By Application - Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Chimeric Antigen Receptor T Cell Therapy Market Size, 2021 & 2028
6.2 By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue & Forecasts
  6.2.1 By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2022
  6.2.2 By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2023-2028
  6.2.3 By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2028
  6.3.2 US Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.3.3 Canada Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.3.4 Mexico Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2028
  6.4.2 Germany Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.4.3 France Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.4.4 U.K. Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.4.5 Italy Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.4.6 Russia Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.4.7 Nordic Countries Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.4.8 Benelux Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2028
  6.5.2 China Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.5.3 Japan Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.5.4 South Korea Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.5.5 Southeast Asia Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.5.6 India Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2028
  6.6.2 Brazil Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.6.3 Argentina Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2028
  6.7.2 Turkey Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.7.3 Israel Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028
  6.7.5 UAE Chimeric Antigen Receptor T Cell Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Amgen
  7.1.1 Amgen Corporate Summary
  7.1.2 Amgen Business Overview
  7.1.3 Amgen Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.1.4 Amgen Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.1.5 Amgen Key News
7.2 Bellicum Pharmaceuticals
  7.2.1 Bellicum Pharmaceuticals Corporate Summary
  7.2.2 Bellicum Pharmaceuticals Business Overview
  7.2.3 Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.2.4 Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.2.5 Bellicum Pharmaceuticals Key News
7.3 Bluebird Bio
  7.3.1 Bluebird Bio Corporate Summary
  7.3.2 Bluebird Bio Business Overview
  7.3.3 Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.3.4 Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.3.5 Bluebird Bio Key News
7.4 Caribou Biosciences
  7.4.1 Caribou Biosciences Corporate Summary
  7.4.2 Caribou Biosciences Business Overview
  7.4.3 Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.4.4 Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.4.5 Caribou Biosciences Key News
7.5 Celgene Corporation
  7.5.1 Celgene Corporation Corporate Summary
  7.5.2 Celgene Corporation Business Overview
  7.5.3 Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.5.4 Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.5.5 Celgene Corporation Key News
7.6 Cellectis
  7.6.1 Cellectis Corporate Summary
  7.6.2 Cellectis Business Overview
  7.6.3 Cellectis Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.6.4 Cellectis Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.6.5 Cellectis Key News
7.7 Celyad Oncology
  7.7.1 Celyad Oncology Corporate Summary
  7.7.2 Celyad Oncology Business Overview
  7.7.3 Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.7.4 Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.7.5 Celyad Oncology Key News
7.8 Gilead Sciences
  7.8.1 Gilead Sciences Corporate Summary
  7.8.2 Gilead Sciences Business Overview
  7.8.3 Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.8.4 Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.8.5 Gilead Sciences Key News
7.9 Intellia Therapeutics
  7.9.1 Intellia Therapeutics Corporate Summary
  7.9.2 Intellia Therapeutics Business Overview
  7.9.3 Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.9.4 Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.9.5 Intellia Therapeutics Key News
7.10 Johnson & Johnson
  7.10.1 Johnson & Johnson Corporate Summary
  7.10.2 Johnson & Johnson Business Overview
  7.10.3 Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.10.4 Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.10.5 Johnson & Johnson Key News
7.11 Legend Biotech
  7.11.1 Legend Biotech Corporate Summary
  7.11.2 Legend Biotech Business Overview
  7.11.3 Legend Biotech Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.11.4 Legend Biotech Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.11.5 Legend Biotech Key News
7.12 Merck
  7.12.1 Merck Corporate Summary
  7.12.2 Merck Business Overview
  7.12.3 Merck Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.12.4 Merck Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.12.5 Merck Key News
7.13 Noile-Immune Biotech
  7.13.1 Noile-Immune Biotech Corporate Summary
  7.13.2 Noile-Immune Biotech Business Overview
  7.13.3 Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.13.4 Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.13.5 Noile-Immune Biotech Key News
7.14 Novartis
  7.14.1 Novartis Corporate Summary
  7.14.2 Novartis Business Overview
  7.14.3 Novartis Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.14.4 Novartis Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.14.5 Novartis Key News
7.15 Pfizer
  7.15.1 Pfizer Corporate Summary
  7.15.2 Pfizer Business Overview
  7.15.3 Pfizer Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.15.4 Pfizer Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.15.5 Pfizer Key News
7.16 Sangamo Therapeutics
  7.16.1 Sangamo Therapeutics Corporate Summary
  7.16.2 Sangamo Therapeutics Business Overview
  7.16.3 Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.16.4 Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.16.5 Sangamo Therapeutics Key News
7.17 Servier Laboratories
  7.17.1 Servier Laboratories Corporate Summary
  7.17.2 Servier Laboratories Business Overview
  7.17.3 Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Major Product Offerings
  7.17.4 Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Revenue in Global Market (2017-2022)
  7.17.5 Servier Laboratories Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Chimeric Antigen Receptor T Cell Therapy Market Opportunities & Trends in Global Market
Table 2. Chimeric Antigen Receptor T Cell Therapy Market Drivers in Global Market
Table 3. Chimeric Antigen Receptor T Cell Therapy Market Restraints in Global Market
Table 4. Key Players of Chimeric Antigen Receptor T Cell Therapy in Global Market
Table 5. Top Chimeric Antigen Receptor T Cell Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chimeric Antigen Receptor T Cell Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chimeric Antigen Receptor T Cell Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chimeric Antigen Receptor T Cell Therapy Product Type
Table 9. List of Global Tier 1 Chimeric Antigen Receptor T Cell Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chimeric Antigen Receptor T Cell Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chimeric Antigen Receptor T Cell Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chimeric Antigen Receptor T Cell Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chimeric Antigen Receptor T Cell Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chimeric Antigen Receptor T Cell Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Amgen Corporate Summary
Table 31. Amgen Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 32. Amgen Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Bellicum Pharmaceuticals Corporate Summary
Table 34. Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 35. Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Bluebird Bio Corporate Summary
Table 37. Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 38. Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 39. Caribou Biosciences Corporate Summary
Table 40. Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 41. Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Celgene Corporation Corporate Summary
Table 43. Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 44. Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Cellectis Corporate Summary
Table 46. Cellectis Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 47. Cellectis Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Celyad Oncology Corporate Summary
Table 49. Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 50. Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Gilead Sciences Corporate Summary
Table 52. Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 53. Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 54. Intellia Therapeutics Corporate Summary
Table 55. Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 56. Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 57. Johnson & Johnson Corporate Summary
Table 58. Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 59. Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 60. Legend Biotech Corporate Summary
Table 61. Legend Biotech Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 62. Legend Biotech Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 63. Merck Corporate Summary
Table 64. Merck Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 65. Merck Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 66. Noile-Immune Biotech Corporate Summary
Table 67. Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 68. Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 69. Novartis Corporate Summary
Table 70. Novartis Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 71. Novartis Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 72. Pfizer Corporate Summary
Table 73. Pfizer Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 74. Pfizer Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 75. Sangamo Therapeutics Corporate Summary
Table 76. Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 77. Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)
Table 78. Servier Laboratories Corporate Summary
Table 79. Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Product Offerings
Table 80. Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Chimeric Antigen Receptor T Cell Therapy Segment by Type in 2021
Figure 2. Chimeric Antigen Receptor T Cell Therapy Segment by Application in 2021
Figure 3. Global Chimeric Antigen Receptor T Cell Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chimeric Antigen Receptor T Cell Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chimeric Antigen Receptor T Cell Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chimeric Antigen Receptor T Cell Therapy Revenue in 2021
Figure 8. By Type - Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 12. US Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 24. China Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chimeric Antigen Receptor T Cell Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chimeric Antigen Receptor T Cell Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Amgen Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bellicum Pharmaceuticals Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bluebird Bio Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Caribou Biosciences Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Celgene Corporation Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Cellectis Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Celyad Oncology Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Gilead Sciences Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Intellia Therapeutics Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Johnson & Johnson Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Legend Biotech Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Merck Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Noile-Immune Biotech Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Novartis Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Pfizer Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Sangamo Therapeutics Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Servier Laboratories Chimeric Antigen Receptor T Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)